[Federal Register Volume 85, Number 130 (Tuesday, July 7, 2020)]
[Notices]
[Page 40687]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-14605]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-672]


Importer of Controlled Substances Application: Lipomed

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before August 6, 2020. 
Such persons may also file a written request for a hearing on the 
application on or before August 6, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
request for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on June 4, 2020, Lipomed, 150 Cambridgepark Drive, Suite 
705, Cambridge, Massachusetts 02140, applied to be registered as an 
importer of the following basic class(es) of controlled substances:

------------------------------------------------------------------------
          Controlled substance               Drug code       Schedule
------------------------------------------------------------------------
Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-            7036               I
 3-carboxamido) 3,3-dimethylbutanoate)..
N-(Adamantan-1-yl)-1-(4-fluorobenzyl)-1H-           7047               I
 indazole-3-carboximide)................
1-(5-Fluoropentyl)-1H-indazole-3-                   7083               I
 carboxamide............................
4-methyl-alpha-ethylaminopentiophenone              7245               I
 (4-MEAP)...............................
N-ethylhexedrone........................            7246               I
4-chloro-alpha-pyrrolidinovalerophenone             7443               I
 (4-chloro-a-PVP).......................
[alpha]-PHP, alpha-                                 7544               I
 Pyrrolidinohexanophenone...............
PV8, alpha-Pyrrolidinoheptaphenone......            7548               I
Norfentanyl.............................            8366               I
------------------------------------------------------------------------

    The company plans to import the above controlled substances as 
analytical reference standards for distribution to its customers for 
research and analytical purposes. Placement of these drug codes onto 
the company's registration does not translate into automatic approval 
of subsequent permit applications to import controlled substances. 
Approval of permit applications will occur only when the registrant's 
business activity is consistent with what is authorized in 21 U.S.C. 
952(a)(2). Authorization will not extend to the import of Food and Drug 
Administration (FDA)-approved or non-approved finished dosage forms for 
commercial sale.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-14605 Filed 7-6-20; 8:45 am]
BILLING CODE P